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A B S T R A C T 
 
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK 
fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. 
Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel “basket” study which 
has enrolled patients from infants to elderly with different TRK fusion-positive cancers. In this review, we focus 








Cancer is normally classified and treated according to its pathologic 
features and the tissue/organ of origin. Recently, thanks to the new 
sequencing technologies and large-scale genomics approaches such as 
The Cancer Genome Atlas (TCGA) and the International Cancer Genome 
Consortium (ICGC), several driver genetic alterations have been iden- 
tified as useful biomarkers and targets for innovative cancer ther- 
apeutics. These discoveries have driven cancer sub-classification to a 
genetic alteration-based categorization (Zhang et al., 2019; Weinstein  
et al., 2013). 
In agreement with this approach, lung adenocarcinoma has been 
subclassified taking into consideration possible translocations of ALK 
and ROS genes or mutations of KRAS and EGFR genes (Chang et al., 
2015). The discovery of these genetic alterations has also brought to a 
substantial change toward precision cancer therapeutic strategies. More 
recently several other driver genetic alterations in this disease have 
been identified as a well as in a variety of other common and less 
common tumours (Chen and Chi, 2018). 
For example, the BRAFV600 mutation is frequently observed in 
melanoma, colorectal cancer, hairy cell leukaemia and thyroid cancer, 
whereas it has been rarely reported in other cancers including lung 
adenocarcinoma (Hyman et al., 2015). For this particular mutation, 
variable objective response rates have been achieved ranging from 0% 
 
in colorectal cancer to more than 40 % in mutant melanoma and non- 
small cell lung cancer (Hyman et al., 2015; Flaherty et al., 2010). Thus, 
despite a hypothesized uniform activity of potent selective BRAFV600 
inhibitors in different tumour types harbouring the aforementioned 
mutated oncoprotein, as a consequence of their identical site of action, 
the variable tumour-specific cellular context may markedly impact on 
tissue lineage-specific primary resistance to treatment (Prahallad et al., 
2012). 
More recently, a novel therapeutic opportunity has emerged from 
the presence of oncogenic rearrangements of neurotrophic tropomyosin 
receptor kinase (NTRK) genes 1, 2, and 3. These genes encode for 
NTRKA, B, and C proteins that have been first found, although rarely, in 
common tumours such as colorectal, glioblastoma, lung and breast 
cancers, and may appear more frequently in a large variety of rare tu- 
mours (Cocco et al., 2018), and represent novel biomarkers and targets 
for cancer therapy. The response observed in diverse cancers to TRK 
inhibition has provided the first example of the histology-independent 
activity in a molecularly defined subset of cancers (Drilon et al., 2017, 
2018). 
This mini-review aims to summarize the role of NTRK gene fusions 







Fig. 1. Tropomyosin receptor kinases TRKA, TRKB and TRKC and their path- 
ways. 
 
2. TRK gene and signalling 
 
Tropomyosin receptor kinases (TRK) including TRKA, TRKB and 
TRKC are tyrosine kinases receptors encoded by NTRK1, NTRK2 and 
NTRK3 genes usually expressed in the nervous system (Chao, 2003) 
Fig. 1. NTRK1 is mapped on chromosome 1q21-q22 (Weier et al., 1995) 
and encodes for a 796 residue protein (TRKA receptor) with an in- 
tracellular domain containing a short C-terminal tail, a TK domain and 
a juxtamembrane region (Mardy et al., 1999). Mutations altering the 
function of TRKA protein are reported in patients affected by the con- 
genital insensitivity to pain with anhidrosis syndrome (CIPA) (Mardy 
et al., 1999). NTRK2 is located on chromosome 9q22.1 (Nakagawara    
et al., 1995) and includes 24 exons (Yeo et al., 2004) and encodes for an 
822-residue protein (TRKB receptor) made of 2 immunoglobulins (Ig)- 
like domains, followed by a cysteine-rich domain, a leucine-rich do- 
main, a second cysteine-rich domain and an N-terminal signal se- 
quence. These sequences assemble the C-terminal PLCγ-docking site, a 
TK domain close to the C-terminus, an Src homology 2 domain, a 
transmembrane domain and the BDNF-binding region. The NTRK3 gene 
is found on chromosome 15q25 (Valent et al., 2020) and consist of a  
145 kD glycoprotein mainly expressed in the human granular cell layer 
of cerebellum, hippocampus and cerebral cortex (Lamballe et al.,  
1991). 
Reported functions of tyrosine kinases receptors are the promotion 
of synaptic plasticity and neuronal survival in the central nervous 
system once activated by tethering to complete neurotrophins such as 
the nerve growth factor (NGF) for TRKA, brain-derived growth factor 
(BDGF) for TRKB and Neurotrophin-3 (NT3) for TRKC (Chao, 2003). 
Some genetic alterations in NTRK genes such as translocations can 
cause TRK fusion proteins, leading to ligand-independent activation of 
TRK proteins and thus promoting the oncogenic process (Amatu et al., 
2016; Martin-Zanca et al., 1986; Vaishnavi et al., 2015a). All TRK re- 
ceptors (A, B and C) consist of an intracellular domain with a kinase 
 
 
domain, a transmembrane domain and an extracellular domain for li- 
gand binding. The ligand binding initiates the process of oligomeriza- 
tion which if followed by the specific tyrosine residues 
phosphorylation in the intracytoplasmic kinase domain. This step 
leads to the activation of the pathway for proliferation, differentiation 
and survival in normal and malignant cells (Nakagawara, 2001). 
The NGF binding to TRKA receptor triggers the activation of the 
Ras/Mitogen-activated protein kinase (MAPK) signalling pathway, 
leading to a higher rate of proliferation and cell growth via the 
Extracellular Signal-Regulated Kinase (ERK) pathway. TRKB triggers 
the BDNF signal through the PLCγ, PI3K and Ras-ERK pathway, 
turning into survival and neuronal differentiation whereas the 
coupling of NT3 with TRKC leads to the activation of the PI3/AKT 
pathway, increasing cell survival and precluding apoptosis 
(Nakagawara, 2001). 
So far, more than 20 different types of cancer are supposed to be 
promoted by TRK fusion proteins. Except for some uncommon 
cancers such as congenital infantile fibrosarcoma, salivary gland 
mammary analog secretory carcinoma, congenital mesoblastic 
nephroma and se- cretory breast carcinoma, TRK genetic alterations 
has been observed in common cancers such as colorectal cancer, non-
small cell lung cancer, breast ductal carcinoma, acute myeloid 
leukaemia and soft tissue sar- comas, although with low frequency 
(Amatu et al., 2016; Vaishnavi    et al., 2015a; Knezevich et al., 1998; El 
Demellawy et al., 2016; Frattini et al., 2013; Zheng et al., 2014; Shi et 
al., 2016; Brenca et al., 2016; Wu   et al., 2014; Bourgeois et al., 2000; 
Ross et al., 2014; Vaishnavi et al., 2013; Jones et al., 2013; Prasad et al., 
2016; Wajjwalku et al., 1992; Braghiroli et al., 2016; Stransky et al., 
2014; Tognon et al., 2002; Krings et al., 2017; Créancier et al., 2015; 
Ardini et al., 2014;  Rubin et  al.,  1998) (Table 1). Thus, the clinical 
assessment of TRK inhibition still represents a great challenge mainly 
due to the heterogeneity of tumour types and the low frequency of 
TRK fusions. 
 
3. TRK inhibitor larotrectinib demonstrates efficacy in a 
basket trial 
 
Larotrectinib (ARRY470, Vitrakvi, LOXO101) is a new highly se- 
lective small agent and a potent inhibitor of the three TRK fusion 
proteins which has been recently assessed by Drilon and his 
colleagues (Drilon et al., 2018). Larotrectinib selectively blocks the 
ATP-binding site of TRK-family receptors with  a  50  %  inhibitory  
constant  of  5−11 nmol/L in vivo (Vaishnavi et al., 2015b). The drug 
did not show activity when assessed on a panel of 226 non-TRKs 
whereas G1 cell- cycle arrest and apoptotic ability were observed 
when evaluated on in vitro assay of TRK-expressing tumours (Doebele 
et al., 2015). Moreover, larotrectinib corroborated the in vivo dose-
dependent tumour inhibi- tion on athymic nude mice (Doebele et al., 
2015). In terms of phar- macokinetics, larotrectinib is rapidly absorbed 
after oral administration with a plasma concentration peak of 0.5−2 
hours and an avarage half- life of 1.5−2 hours in both children and 
adults (Laetsch et al., 2018). However, the nasogastric and 
gastrostomic administration were also allowed for patients unable to 
orally take the drug and no food re- strictions were required in 
clinical trials. Although its linear pharma- cokinetic pattern with 
different dosing approaches, no drug accumu- lation was reported. 
The CYP3A4 is the key player in terms of drug metabolization while 
its elimination is performed by biliary and renal apparatus (Laetsch et 
al., 2018). 
The safety and efficacy profile of larotrectinib was evaluated in the 
novel phase I/II “basket” clinical trial which enrolled patients based 
on their NTRK genetic alterations, regardless of their tumour type or 
age (Drilon et al., 2018). The trial involved 55 patients, aged between 
4 months and 76 years old with 16 different tumour types, who were 
treated complying with three different protocols and the results were 
pooled. Drilon and colleagues showed that larotrectinib was overall 
well-tolerated with grade 3 or 4 adverse events (AE) reported by less 
than 5% of patients. Generally, the Response Evaluation Criteria in 
Solid Tumours (RECIST) response rate was 80 % (95 % confidence 
 
 
Different malignancies with rare TRK fusions. 
Malignancy NTRK gene involved (frequency) Methodology used 
 
Astrocitoma NTRK2 (3/96 = 3.1 %) Whole-genomeSeq, RNA-seq (Zhang et al., 2019) 
Appendiceal adenocarcinoma NTRK (unspecified) (2/97 = 2.1 %) Targeted NGS (Weinstein et al., 2013) 
Brain Low-grade glioma NTRK2  (2/461 = 0.435) RNA-seq (TCGA) (Chang et al., 2015) 
Brain invasive carcinoma NTRK3 (1/1072 = 0.09 %) RNA-seq (TCGA) (Chang et al., 2015) 
Breast secretory carcinoma NTRK3 (12/1392.3 %) RT-PCR, FISH (Chen and Chi, 2018) 
NTRK3 (9/9 = 100 %) Targeted NGS, FISH (Hyman et al., 2015) 
Colon adenocarcinoma NTRK1 (8/1559 = 0,51 %) IHC, RT-PCR (Flaherty et al., 2010) 
NTRK1 (1/66 = 1.5 %) IHC, RT-PCR (Prahallad et al., 2012) 
NTRK3 (2/286 = 0.69 %) RNA-seq (TCGA) (Chang et al., 2015) 
Congenital mesoblastic nephroma NTRK3 (5/6 = 83 %) RT-PCR, FISH (Cocco et al., 2018) 
NTRK3 (10/15 = 66.6 %) RT-PCR (Drilon et al., 2017) 
NTRK3 (13/19 = 68.4 %) FISH (Drilon et al., 2018) 
Glioblastoma NTRK1 (1/157 = 0.63 %) RNA-seq (TCGA) (Chang et al., 2015) 
NTRK1 (2/185 = 1.08 %)) RNA-seq (TCGA and other) (Chao, 2003) 
NTRK1 (3/115 = 2.6 %)) Targeted NGS (Weier et al., 1995) 
GIST NTRK3 (1/186 = 0.53 %) Targeted NGS (Mardy et al., 1999) 
NTRK3 (1/31 = 3.2 %) RNA-seq, RT-PCR, FISH (Nakagawara et al., 1995) 
Head and Neck squamous cell carcinoma NTRK2 (1/411 = 0.24 %) RNA-seq (TCGA) (Chang et al., 2015) 
NTRK3 (1/411 = 0.24 %) RNA-seq (TCGA) (Chang et al., 2015) 
High-grade glioma NTRK2 (3/127 = 2.36 %) Whole-genome seq, RNA-seq(Yeo et al., 2004) 
NTRK3 (2/127 = 1.57 %) Whole-genome seq, RNA-seq(Yeo et al., 2004) 
Infantil congenital fibrosarcoma NTRK3 (10/11 = 90.9 %) IHC, RT-PCR (Valent et al., 2020) 
NTRK3 (5/5 = 100 %) RT-PCR, FISH (Cocco et al., 2018) 
Intrahepatic cholangiocarcinoma NTRK1 (1/28 = 3.6 %) Targeted NGS (Lamballe et al., 1991) 
Lung adenocarcinoma NTRK1 (3/91 = 3.29 %) FISH, targeted NGS (Chang et al., 2015) 
NTRK2 (1/513 = 0.19 %) RNA-seq (TCGA) (Amatu et al., 2016) 
Melanoma NTRK3 (1/374 = 0.26 %) RNA-seq (TCGA) (Chang et al., 2015) 
Non-brain stem and pediatric diffuse intrinsic pontine glioma (DIPG) NTRK1 (3/127 = 2.36 %)) Whole-genome seq, RNA-seq (Yeo et al., 2004) 
Papillary Thyroid Carcinoma NTRK1 (15/119 = 12.6 %)) RT-PCR (Martin-Zanca et al., 1986) 
NTRK1 (2/38 = 5.2 %) Southern (Vaishnavi et al., 2015a) 
NTRK1 (pediatric) (1/27 = 3.7 %) Targeted NGS (Nakagawara, 2001) 
NTRK3 (2/26 = 7.69 %) RNA-seq (Jones et al., 2013) 
NTRK3 (9/62 = 14.5 %) RNA-seq (Braghiroli et al., 2016) 
NTRK3 (sporadic) (3/51 = 5.8 %) RNA-seq (Braghiroli et al., 2016) 
NTRK3 (pediatric) (6/27 = 22.2 %) Targeted NGS (Nakagawara, 2001) 
Ph-like acute lymphoblastic leukemia NTRK3 (1/154 = 0.64 %) Whole-genome/exome seq, RNA-seq(Stransky et al., 2014) 
Salivary glands secretory carcinoma 
Mammary analogue (MASC) 
NTRK3(13/14 = 92.8 %) FISH, RT-PCR (Tognon et al., 2002) 
NTRK3 (15/15 = 100 %) FISH (Krings et al., 2017) 
NTRK3 (5/6 = 83.3 %) Targeted NGS, FISH (Hyman et al., 2015) 
NTRK3 (16/20 = 80 %) FISH, RT-PCR (Créancier et al., 2015) 
Sarcoma NTRK1 (1/103 = 0.97 %) RNA-seq (TCGA) (Chang et al., 2015) 
Spitzoid melanoma and Spitz tumours NTRK1 (23/140 = 16.4 %) IHC, FISH, targeted NGS (Ardini et al., 2014) 
Tyroid carcinoma NTRK1 (5/498 = 1,0%)) RNA-seq (TCGA) (Chang et al., 2015) 
NTRK3 (7/498 = 1,4%) RNA-seq (TCGA) (Chang et al., 2015) 
Uterine sarcoma NTRK1 (3/97 = 3.09 %) Targeted NGS, IHC, FISH, RNA-seq (Rubin et al., 1998) 
NTRK3 (1/97 = 1.03 %) Targeted NGS, IHC, FISH, RNA-seq (Rubin et al., 1998) 
 
interval, 61–85) by investigator assessment and 75 % (95 % confidence 
interval, 61–85) by independent review. 75 % of patients were on a 
continuous response to the treatment and 55 % of patients were pro- 
gression-free after 1 year. However, after a median follow-up of 8.3 and 
9.9 months, the average duration of response and progression-free 
survival (PFS) were both not achieved, even though effective responses 
were reported for most patients regardless of age group and tumour 
type. Despite the molecular identification of TRK fusion at a screening 
level, three out of six patients did not show any response to laro- 
trectinib. This failure could be due to primary drug-resistance since no 
TRK proteins was detected by immunochemistry (IHC). 
Secondary mutations in NTRK1 or NTRK3 genes including the xDFG 
position (NTRK1 G667S or NTRK3 G696A), gatekeeper mutation 
(NRTK1 F589 L) and substitutions in the front position of solvent 
(NTRK1 G595R or NTRK3 G623R) were detected in nine out of ten 
patients who progressed after a 6 months initial response. This acquired 
mechanism of resistance to larotrectinib is known to be shared by other 
oncogenic kinase-targeted therapies (Katayama et al., 2012; Kobayashi 
et al., 2005; Core et al., 2014) and, to overcome this issue, a new 
generation of TRK inhibitors are under development (Mardy et al., 
1999; Lamballe et al., 1991; Amatu et al., 2016; Martin-Zanca et al., 
1986; Nakagawara, 2001; Jones et al., 2013) (Table 2). 
4. Future perspectives 
 
The aforementioned study by Drilon and colleagues (Drilon et al., 
2018) comes on the heels of several basket trials that specifically in- 
vestigated, although reporting controversial clinical results the pan- 
HER kinase inhibitor neratinib in HER2 and HER3 mutant neoplasms 
(Hyman et al., 2018), the PD1 inhibitor pembrolizumab in mismatch 
repair deficient neoplasms (Le et al., 2017) and the AKT inhibitor ca- 
pivasertib (AZD5363) in AKT1 E17 K mutant neoplasms (Hyman et al., 
2017). Drilon’s study represents a novel intriguing and efficient mole- 
cular-driven “basket” approach investigating a different group of tu- 
mours with uncommon driver mutations. The aim of the study is to 
open a window on a new set of treatments for patients with rare driver 
mutations in tumours. However, Drilon and colleagues did not report 
data on median duration of response, progression-free survival and 
long-term safety with several cancers types such as colon, lung, breast 
and melanoma lacking in the study. Therefore, subsequent analysis has 
been performed to evaluate the efficacy and long-term safety of laro- 
trectinib in a larger population of patients with TRK fusion-positive 
solid tumours (Hong et al., 2020). A total of 159 patients with TRK 
fusion-positive cancer, including the previously evaluated 55 patients 
by Drilon, were enrolled and treated with larotrectinib. Of note, the 
 
 
Active clinical trials assessing TRK inhibitors. 
Drug name Targets Stage Trial Identifier Company 
MGCD516 (Sitravatinib) MET, AXL, RET, NTRK1/2/3, DDR2, KDR, PDGFRA, KIT or CBL Phase I/Ib NCT02219711 Mirati Therapeutics 
RXDX-101 (Entrectinib) NTRK1/2/3, ROS1, ALK Phase I NCT02097810 Hoffmann-La Roche 
  Phase I/Ib NCT02650401 Hoffmann-La Roche 
  Phase II NCT02568267 Hoffmann-La Roche 
  Phase II NCT03994796 Alliance for Clinical Trials in Ocology 
LOXO-101 (Larotrectinib) NTRK1/2/3 Phase I NCT02122913 Bayer 
  Phase I/II NCT02637687 Bayer 
  Phase II NCT03834961 Children's Oncology Group 
  Phase II NCT03213704 National Cancer Institute (NCI) 
  Phase II NCT02576431 Bayer 
LOXO-195 (Selitrectinib) NTRK1/2/3 (resistant) Phase I/II NCT03215511 Loxo Oncology 
    Bayer 
  Phase I NCT04275960 Bayer 
DS-6051b NTRK1/2/3, ROS1 Phase I NCT02279433 Daiichi Sankyo 
  Phase I NCT02675491 Daiichi Sankyo 
LY2801653 (Merestinib) NTRK1/2/3, ROS1, TEK, MERTK, MST1RR, FLT3, AXL, DDR1/2, MKNK1/2 Phase II NCT02920996 Dana-Farber Cancer Institute 
    Eli Lilly and Company 
Cabozantinib RET, NTRK1/2/3, MET, AXL, ROS1 Phase II NCT01639508 Memorial Sloan Kettering Cancer Center 
VMD-928 NTRK1 Phase I NCT03556228 VM Oncology LLC 
TPX-0005 (Repotrectinib) NTRK1/2/3, ALK, ROS1 Phase I/II NCT03093116 Turning Point Therapeutics 
  Phase I/II NCT04094610 Turning Point Therapeutics 
 
proportion of patients with an objective response was approximately 80 
% according to investigator assessment (similar to the data previously 
reported by Drilon et al.) with 16 % of patients who achieved a com- 
plete response. In addition, the median duration of response with lar- 
otrectinib was 35.2 months and the median progression-free survival 
was 28.3 months. Finally, the proportion of patients with TRK fusion- 
positive cancer who had a dose reduction because of adverse events was 
8 % with only 2 % of patients who discontinued drug because of a drug- 
related adverse event (Hong et al., 2020). In 2019, Rosen et al. iden- 
tified 76 cases with confirmed TRK fusions (0.28 % overall prevalence) 
from a centre-wide screening program involving more than 26.000 
prospectively sequenced patients (Rosen et al., 2020). The authors 
showed that the presence of a TRK fusion is negatively correlated with 
the presence of simultaneous concurrent oncogenic drivers mutation 
but positively associated with a lower tumour mutation burden with the 
only exception the concomitant presence of TRK fusion and micro- 
satellite instability (MSI-H) in colorectal cancer. Besides, the authors 
reported that alternative standards of care, excluding immunotherapy, 
are effective for TRK fusion-positive cancers. 
Entrectinib is an inhibitor of TRKA, B, C and ROS1, with demon- 
strated activity against central nervous system (Liu et al., 2018). More 
recently, data on the integrated efficacy and safety from two phase 1 
trials (ALKA-372-001 and STARTRK-1) and one phase 2 trial 
(STARTRK-2), which have enrolled NTRK fusion-positive patients with 
metastatic or locally advanced solid tumours including patients with 
gastrointestinal cancers, confirmed the safety and efficacy of entrectinib 
for patients with NTRK fusion-positive solid tumours (Doebele et al., 
2020; Siena et al., 2020). 
Although all together these data suggest positive outcomes for the 
use of TRK inhibitors in cancer treatment, there are important issues 
and questions that should be addressed. 
In diagnostic pathology, NTRK gene fusions can be detected in tissue 
specimens by a variety of methods, including next-generation sequen- 
cing (NGS), targeted RNA sequencing, reverse transcriptase PCR (RT- 
PCR), fluorescence in situ hybridization (FISH) and im- 
munohistochemistry (IHC). Each of these approaches shows specific 
advantages and drawbacks (Table 3). 
Initially, FISH and RT-PCR have been widely used to achieve a low- 
cost detection of NTRK fusions in tumours with a high TRK prevalence 
and known NTRK fusions involving recurrent partners. For tumour 
types such as secretory breast cancer (with the ETV6-NTRK3 gene fu- 
sion with pathognomonic significance) and congenital infantile 
fibrosarcoma, a single gene testing approach could be more suitable. 
Indeed, the FISH method has the advantage of being able to detect 
novel fusion partners if break-apart probes are used. The technique per 
se, however, does not allow the use of three probes at the same time for 
the same specimen. Therefore, for unknown fusions, three sets of break- 
apart FISH probes (i.e. one for each NTRK gene) are required. 
RT-PCR is another highly sensitive and widespread methodology 
that enables the detection of fusion transcripts with known partners, 
reducing the costs and the turnaround time for well-characterized 
NTRK-tumours that, generally, are also very rare (Bubendorf et al., 
2016; Church et al., 2018). 
More recently, novel NGS technologies have emerged as mainstream 
testing platforms with the advantage of identifying multiple potential 
drivers in addition to NTRK gene fusions. However, the detection of 
NTRK gene fusions by multiplex targeted exome capture panels (e.g., 
MSK-IMPACT™, Foundation One®) may be challenging due to the pre- 
sence of large intronic regions. It may be considered that both DNA- and 
RNA-based NGS assays are relatively labour intensive and cost-prohi- 
bitive for many laboratories: the former DNA-based assays do not 
identify novel fusions and have a moderate false-positive and false- 
negative rate whereas the latter RNA-based assays, have compelling 
sensitivity and novel fusion detection capability. The benefit of RNA- 
based NGS assays is the capability to recognize fusion gene transcript 
variants as well as levels of fusion gene transcript expression. Examples 
of currently available commercial NGS assays with the capacity to de- 
tect NTRK gene fusions are the Illumina TruSight Tumor 170, the 
Thermo Fisher Oncomine™ Focus and the Oncomine™ Comprehensive 
panels (Illumina, 2020; Thermofisher, 2020; Bartlett, 2020). Sample 
(DNA versus RNA) and bioinformatic requirements, as well as the as- 
sociated enrichment methods, vary between these kits with a con- 
sequent impact on their detection capabilities (Albert et al., 2019). In 
the short term, approval of NGS‐based tests and achievement of broad 
insurance coverage for NGS‐based testing are major challenges. 
TRK expression can be also identified with IHC with reasonable 
sensitivity and efficiency (Rudzinski et al., 2018; Hechtman et al.,  
2017). However, IHC does not easily discriminate TRK fusion proteins 
arising from genetic alterations that targeted by TRK inhibitors, espe- 
cially in tumours where TRK function and clinical impact remain poorly 
known. In some cancers and tumour tissues, the detection of TRK fusion 
proteins with IHC is associated with false positives especially when TRK 
proteins may be normally expressed, e.g. in neuroblastoma (Albert     












Low-cost Labour intensive 
 
   Good specificity   
FISH   Low-cost Labour intensive  
   Good specificity   
IHC   Low-cost Expensive multiplexing approach  
   Good sensitivity and efficiency Moderate false-positive rate  
   Good for uncommon malignancies with TRK-high frequency Difficult TRK fusion detection  
   Largely available in most labs   
NGS DNA-based  Multiple target detection (High throughput) No novel fusion detection  
   Higher sensitivity Moderate false-positive and false-negative rate  
   Targeted tumour-sequencing test Low-accuracy with large intronic regions  
    Expert bioinformatic staff required  
 RNA-based  Targeted tumour-sequencing test Cost-prohibitive  
   Novel fusion detection   
   Good sensitivity   
   Multiple target detection (High throughput)   
   Gene transcripts variants detection   
 
might be expensive and require great effort. Consequently, the appli- 
cation of pan-NTRK IHC as a rapid routine diagnostic screening tool for 
common tumours with low TRK prevalence (such as colorectal cancer) 
is currently under debate. 
Given the variety of malignancies targeted by TRK inhibitors, in 
both the adult and pediatric population, and the relative low number of 
patients included in the clinical trials, there is the urgent need to better 
identify NTRK gene fusions expression in each tumour type. As reported 
by Albert et al, a simultaneous approach with IHC,FISH and RT-PCR is 
suggested for pediatric tumours with high TRK fusion frequency, al- 
though the initial IHC screening followed by NGS testing is currently 
preferred (Albert et al., 2019). Unfortunately, theexisting limited in- 
formation does not allow yet to discriminate between NGS (for the 
detection of NTRK alterations) and IHC (for the evaluation of TRK ex- 
pression) as predictors of the response to TRK inhibitors. 
Despite the identification of NTRK alterations by NGS in 3 out of 6 
patients, these patients did not respond to larotrectinib and did not 
show a clear expression of TRK fusion proteins with the use of pan-TRK 
IHC (Drilon et al., 2018). Therefore, it might be speculated that TRK 
expression and IHC identification are both necessary for the evaluation 
of the clinical response. Nowadays, Illumina NGS (DNA and RNA assays 
in a single design) and Pan-TRK IHC are both being introduced as 
complementary diagnostic tests for the treatment with larotrectinib and 
other TRK inhibitors. Although TRK IHC would be a sensible starting 
diagnostic tool for rare cancers with TRK fusions and possibly for 
common cancers without driver mutations, the better characterization 
of a single assay, capable of identifying druggable genetic alterations, is 
urgently needed. Finally, in the foreseeable future, several trials are 
awaited to investigate possible mechanisms of natural and/or acquired 
resistance to TRK inhibitors (Passiglia et al., 2016), including possible 
combinations of these drugs with chemotherapy, immunotherapy or 
targeted therapy. 
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